Swiss Re AG (SWX:SRENE)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 35.13B -17.5% |
| Revenue (ttm) | 34.00B -3.3% |
| Net Income | 3.89B +45.8% |
| EPS | 13.11 +44.2% |
| Shares Out | n/a |
| PE Ratio | 9.02 |
| Forward PE | 9.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,500 |
| Average Volume | 60,300 |
| Open | 121.35 |
| Previous Close | 120.25 |
| Day's Range | 121.05 - 122.40 |
| 52-Week Range | 119.55 - 135.00 |
| Beta | n/a |
| RSI | 34.47 |
| Earnings Date | Aug 6, 2026 |
About Swiss Re AG
Swiss Re AG, together with its subsidiaries, provides reinsurance, insurance, other insurance-based forms of risk transfer, and other insurance-related services worldwide. The company operates through Property & Casualty Reinsurance, Life & Health Reinsurance, and Corporate Solutions segments. The Property & Casualty Reinsurance segment underwrites property reinsurance, including property, credit, surety and political, engineering and project, aviation, marine, agriculture, renewable energy, retakaful, and facultative reinsurance solutions; and... [Read more]
Financial Performance
In 2025, Swiss Re AG's revenue was $42.60 billion, a decrease of -4.17% compared to the previous year's $44.45 billion. Earnings were $4.62 billion, an increase of 45.20%.
Financial numbers in USD Financial StatementsNews
Swiss Re price target lowered to CHF 115 from CHF 118 at Morgan Stanley
Morgan Stanley analyst Hadley Cohen lowered the firm’s price target on Swiss Re (SSREY) to CHF 115 from CHF 118 and keeps an Underweight rating on the shares. Published first…
Swiss Re price target lowered to CHF 132 from CHF 137.64 at Citi
Citi analyst James Shuck lowered the firm’s price target on Swiss Re (SSREY) to CHF 132 from CHF 137.64 and keeps a Neutral rating on the shares. Published first on…
Swiss Re price target lowered to CHF 110 from CHF 118 at RBC Capital
RBC Capital lowered the firm’s price target on Swiss Re (SSREY) to CHF 110 from CHF 118 and keeps an Underperform rating on the shares.
Swiss Re Net Profit Gets Boost From Lower Natural-Catastrophe Losses
The reinsurer said its property-and-casualty segment benefited from low large losses and its life-and-health segment from favorable U.S. mortality trends.
Iran war's Inflationary impact is the key risk to Asia insurers: Swiss Re
Paul Murray, CEO of Life and Health Reinsurance at Swiss Re, says inflation risks in Asia due to the Iran war and rising energy prices are a key concern for the insurance sector in the region. He also...
Swiss Re price target lowered to CHF 118 from CHF 120 at Morgan Stanley
Morgan Stanley analyst Hadley Cohen lowered the firm’s price target on Swiss Re (SSREY) to CHF 118 from CHF 120 and keeps an Underweight rating on the shares. Published first…
Swiss Re price target lowered to CHF 145 from CHF 155 at JPMorgan
JPMorgan analyst Kamran Hossain lowered the firm’s price target on Swiss Re (SSREY) to CHF 145 from CHF 155 and keeps a Neutral rating on the shares. Published first on…
Swiss Re Profit Slips on Lower Revenue
The reinsurer posted a decline in fourth-quarter net profit on a softer top line, falling to $717 million from the $1.05 billion reported the year prior.
Swiss Re downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs downgraded Swiss Re (SSREY) to Sell from Neutral with a CHF 121 price target The firm adjusted ratings in European insurance, saying that although near-term earnings risks are…
Swiss Re price target lowered to CHF 120 from CHF 130 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Swiss Re (SSREY) to CHF 120 from CHF 130 and keeps an Underweight rating on the shares.
Swiss Re downgraded to Neutral from Buy at UBS
UBS downgraded Swiss Re (SSREY) to Neutral from Buy with a price target of CHF 135, down from CHF 150. The firm thinks investors need time and data to ease…
Swiss Re upgraded to Buy from Hold at DZ Bank
DZ Bank upgraded Swiss Re (SSREY) to Buy from Hold with a CHF 160 price target
Swiss Re downgraded to Hold from Buy at Berenberg
Berenberg downgraded Swiss Re (SSREY) to Hold from Buy with a CHF 140 price target The firm sees a balanced risk/reward at current share levels with limited potential for earnings…
Swiss Re downgraded to Neutral from Outperform at Oddo BHF
Oddo BHF analyst Roland Pfaender downgraded Swiss Re (SSREY) to Neutral from Outperform with a price target of CHF 140, down from CHF 160. The firm cites the company’s weaker…
Swiss Re downgraded to Neutral from Buy at Citi
Citi downgraded Swiss Re (SSREY) to Neutral from Buy with a price target of CHF 137.64, down from CHF 169.80. The firm does not see investor sentiment recovering in the…
Swiss Re price target lowered to CHF 155 from CHF 160 at JPMorgan
JPMorgan lowered the firm’s price target on Swiss Re (SSREY) to CHF 155 from CHF 160 and keeps a Neutral rating on the shares.
Swiss Re price target lowered to CHF 118 from CHF 125 at RBC Capital
RBC Capital analyst Ben Cohen lowered the firm’s price target on Swiss Re (SSREY) to CHF 118 from CHF 125 and keeps an Underperform rating on the shares. Published first…
Swiss Re Targets Higher Profit in 2026; Sets Out Buyback Program
The group continues to aim for annual dividend per share growth of 7% or more over next two years and to complement this with an annual share buyback program starting in 2026.
Swiss Re Says Low Natural-Catastrophe Losses Lift Results
Net profit rose to $4 billion for the first nine months of the year, compared with $2.2 billion for the same prior-year period, when it took a hit from an increase in U.S. liability reserves.
Swiss Re downgraded to Underperform from Sector Perform at RBC Capital
RBC Capital analyst Ben Cohen downgraded Swiss Re (SSREY) to Underperform from Sector Perform with a price target of CHF 125, down from CHF 143, as a new analyst took…
JPMorgan downgrades Swiss Re on valuation, softening market
JPMorgan last night downgraded Swiss Re (SSREY) to Neutral from Overweight with a price target of CHF 160, down from CHF 170. The reinsurance market is set to soften into…
Swiss Re downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Swiss Re (SSREY) to Neutral from Overweight with a CHF 160 price target
Swiss Re says GLP-1 drugs could reduce US mortality by up to 6.4%
Reinsurance company Swiss Re said on Wednesday that widespread use of GLP-1 drugs to treat obesity could reduce the annual rate of death by up to 6.4% in the United States by 2045.
CORRECTING and REPLACING Best's Market Segment Report: Swiss Re's Adoption of IFRS 17 Shuffles the Top Tier in AM Best's “World's 50 Largest Reinsurers” Rankings
OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--The figure for Berkshire Hathaway in the fourth paragraph should read: USD 26.9 billion (instead of USD 26.9 million). The updated release reads: BEST'S MA...
Best's Market Segment Report: Swiss Re's Adoption of IFRS 17 Shuffles the Top Tier in AM Best's “World's 50 Largest Reinsurers” Rankings
OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--Swiss Re's adoption of IFRS 17 has resulted in some shifts atop AM Best's rankings of the world's largest reinsurers, which differ based on accounting stan...